Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 2/20 | 0.50 |
| ▸ | PGK2 | P07205 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | FDPS | P14324 | 12/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899018 | 0.80 | PGK1 (0.44) | PGK1PGK2LMNAFDPSLPAR1 | |
| SCHEMBL6898408 | 0.79 | PGK1 (0.48) | PGK1PGK2LMNAFDPSLPAR1 | |
| SCHEMBL6900167 | 0.79 | PGK1 (0.43) | PGK1PGK2LMNAFDPSLPAR1 | |
| SCHEMBL6896204 | 0.79 | PGK1 (0.43) | PGK1PGK2LMNAFDPSLPAR1 | |
| SCHEMBL6900278 | 0.79 | PGK1 (0.43) | PGK1PGK2LMNAFDPSLPAR1 | |
| SCHEMBL14029166 | 0.75 | FDPS (0.54) | PGK1PGK2FDPSLPAR1LPAR3 | |
| SCHEMBL21835980 | 0.71 | LPAR1 (0.57) | FDPSLPAR1LPAR3GGPS1PDE3A | |
| SCHEMBL19792810 | 0.70 | FDPS (0.54) | PGK1PGK2ALDH1A1LMNAFDPS | |
| SCHEMBL21835985 | 0.70 | LPAR1 (0.67) | FDPSLPAR1LPAR3GGPS1 | |
| SCHEMBL37987 | 0.69 | ALDH1A1 (1.00) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165573-B1 | COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES | INST NAT SANTE ETDE LA RECH ME (FR) | 2004-01-21 | — | — | EP | disclosed |
| US-20040009123-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2004-01-15 | — | — | US | disclosed |
| US-20040006131-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2004-01-08 | — | — | US | disclosed |
| US-6624151-B1 | Concerns the uses of said compounds as selective inhibitors of T gamma 9 delta 2 lymphocytes, their uses, for therapeutic purposes. | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2003-09-23 | — | — | US | disclosed |
| EP-1165573-A1 | COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059916-A1 | COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006131-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | CD4, IL2RA, CD74 | PGK1 1638/4885PGK2 1473/4885ALDH1A1 47/4885 |
| US-20040009123-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | CD4, IL2RA, CD74 | PGK1 1638/4885PGK2 1473/4885ALDH1A1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.